SyntekaBio

SyntekaBio EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of SyntekaBio (226330.KQ) as of Nov 20, 2026 is -3.43 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -11.44 B KRW — a change of -70.05% (higher).

EBITDA

-3.43 BKRW

YoY

-70.05%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of SyntekaBio is 2024 -3.43 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of SyntekaBio was 2023 -11.44 B KRW. It decreases by -70.05% higher compared to the previous year.

The SyntekaBio EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
-5.49 B KRW
Jan 1, 2018
3.95 B KRW
Jan 1, 2019
-4.43 B KRW
Jan 1, 2020
-6.04 B KRW
Jan 1, 2021
-7.71 B KRW
Jan 1, 2022
-10.54 B KRW
Jan 1, 2023
-11.44 B KRW
Jan 1, 2024
-3.43 B KRW
The SyntekaBio EBITDA history
YEAREBITDAYoY
-3.43 BKRW-70.05%
-11.44 BKRW+8.52%
-10.54 BKRW+36.79%
-7.71 BKRW+27.62%
-6.04 BKRW+36.27%
-4.43 BKRW-212.33%
3.95 BKRW-171.82%
-5.49 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of SyntekaBio is -3.43 B KRW in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of SyntekaBio changed from -11.44 B KRW to -3.43 B KRW, representing a -70.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SyntekaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — SyntekaBio

All Key Metrics — SyntekaBio